2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
324
Other solid neoplasm
324
Gastrointestinal
53
Gynecologic
43
Genitourinary
35
Breast
29
Head & Neck
22
Sarcoma
21
Dermatologic
20
Lymphoid
12
CNS
11
Endocrine
8
Other hematologic neoplasm
7
Myeloid
5
Plasma cell
3
Other neoplasm
1
NET
1
Conditions
Neuroendocrine Tumors
532
Gastro-enteropancreatic neuroendocrine tumor
58
Carcinoid Tumor
58
Neoplasms
49
Carcinoma, Neuroendocrine
44
Pancreatic Neoplasms
36
Adenoma, Islet Cell
33
Neoplasm Metastasis
28
Pheochromocytoma
26
Paraganglioma
24
Colorectal Neoplasms
24
Stomach Neoplasms
21
Breast Neoplasms
21
Prostatic Neoplasms
20
Lung Neoplasms
20
Carcinoma, Hepatocellular
20
Sarcoma
19
Carcinoma
19
Thyroid Neoplasms
18
Gastrointestinal Neoplasms
18
Neuroblastoma
15
Cholangiocarcinoma
14
Carcinoma, Renal Cell
14
Small Cell Lung Carcinoma
13
Melanoma
13
Esophageal Neoplasms
13
Serotonin Syndrome
12
Colonic Neoplasms
12
Brain Neoplasms
11
Adenocarcinoma
11
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled